



# DURECT Corporation Presenting at The Adams, Harkness & Hill's 22nd Annual Summer Seminar

CUPERTINO, Calif., Aug 5, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the Adams, Harkness & Hill – 22nd Annual Summer Seminar. The conference is being held at The Boston Marriott Long Wharf Hotel. Dr. James E. Brown, President and Chief Executive Officer will be presenting at the conference on Tuesday, August 6, 2002 at 3:30 p.m. EDT. DURECT's presentation will be webcast live for investors and available for replay for a period of 30 days following the conference. The presentation can be accessed in the Investor Relations section at <http://www.durect.com>.

(Photo: <http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO>)

DURECT Corporation ([www.durect.com](http://www.durect.com)) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. In June 2002, DURECT initiated its pivotal phase III program for the CHRONOGESIC(TM) (sufentanil) Pain Therapy System, a 3-month product for the treatment of chronic pain. DURECT owns three proprietary drug delivery platform technologies, including the SABER(TM) Delivery System (a patented and versatile depot injectable useful for protein delivery), the MICRODUR(TM) Biodegradable Microparticulates (microspheres injectable system) and the DURIN(TM) Biodegradable Implant (drug-loaded implant system).

NOTE: CHRONOGESIC(TM) is a trademark of DURECT Corporation. SABER(TM), MICRODUR(TM) and DURIN(TM) are trademarks of Southern BioSystems, Inc., a wholly owned subsidiary of DURECT Corporation. Other trademarks referred to belong to their respective owners.

The statements in this press release regarding DURECT's products in development and product development plans, are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, DURECT's ability to research, develop, manufacture and commercialize its products, obtain product and manufacturing approvals from regulatory agencies, manage its growth and expenses, finance its activities and operations, as well as marketplace acceptance of DURECT's products. Further information regarding these and other risks is included in DURECT's Annual Report on Form 10-K for the fiscal year ended December 31, 2001 filed with the SEC on March 28, 2002, under the heading "Factors that may affect future results," and other periodic reports filed with the SEC. CHRONOGESIC is under development by DURECT and has not been submitted or approved for commercialization by the US Food and Drug Administration or other health authorities.

SOURCE DURECT Corporation



CONTACT:

Schond L. Greenway, Senior Director, Investor Relations and  
Strategic Planning of DURECT Coporation, +1-408-777-1417, or  
[schond.greenway@durect.com](mailto:schond.greenway@durect.com)

/Photo: NewsCom: <http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO>

AP Archive: <http://photoarchive.ap.org>

PRN Photo Desk, +1-888-776-6555 or +1-212-782-2840

URL:

<http://www.durect.com>

<http://www.prnewswire.com>

Copyright (C) 2002 PR Newswire. All rights reserved.